Raymond James resumed coverage on Disc Medicine with a new price target
$IRON
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2025 | $86.00 | Buy | Truist |
| 7/3/2025 | $85.00 | Overweight | Morgan Stanley |
| 6/11/2025 | $89.00 | Strong Buy | Raymond James |
| 2/27/2025 | Buy | TD Cowen | |
| 11/5/2024 | $85.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/4/2024 | $66.00 → $110.00 | Outperform → Strong Buy | Raymond James |
| 10/23/2024 | $89.00 | Buy | Jefferies |
| 10/16/2024 | Sector Outperform | Scotiabank |
WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned NDA submission for bitopertin in EPP. "At the pre-NDA meeting, we confirmed alignment with the agency on the expected timing and content of our NDA submission and, as a result, we are on track for a submission in October of this year," said John Quisel, J.D., Ph.D., Preside
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo
Truist initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $86.00
Morgan Stanley resumed coverage of Disc Medicine with a rating of Overweight and set a new price target of $85.00
Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00
144 - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological
Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that
Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G - Disc Medicine, Inc. (0001816736) (Subject)